Bringing doctors together

or

A free, private network for verified physicians

Leading voices

Dr. Sara Horst

IBD · Vanderbilt

View

Dr. Laura Sahyoun

IBD · WCM

View

Dr. Uma Mahadevan

IBD · UCSF

View

Dr. Deborah Proctor

IBD · Yale College

View

Dr. Saurabh Sethi

General GI · Oja Health

View

Dr. Nneka Ufere

Liver Transplant · MGH

View

Dr. Wendi LeBrett

General GI · ModernGut

View

Dr. Treta Purohit

General GI · Oshi Health

View

Dr. Rushabh Modi

General GI · Kaiser Permanente

View

Dr. Brennan Spiegel

General GI · Cedars-Sinai

View
  • Discover your community

  • Stay current

  • A profile that represents you

  • Find your people

About RoonPrivacyTerms

    Overview

    Phase 2 Trial of Icotrokinra for Patients with Ulcerative Colitis

    Oct 15, 2026DOI: 10.1056/nejmoa2604435Original ArticleNEJM

    Written by: Maria T. Abreu, M.D.Britta Siegmund, M.D.Lindsey Surace, M.D.Ngozi Erondu, M.D., Ph.D.Minhu Chen, M.D., Ph.D.Karen Chachu, M.D., Ph.D.Edouard Louis, M.D., Ph.D.Katsuyoshi Matsuoka, M.D., Ph.D.Jimmy Limdi, M.D.Edmund Arthur, Pharm.D.Nicole Houck, B.S.Colleen Marano, Ph.D.Marion L. Vetter, M.D.Bin Zou, M.D.Joyce Zhan, Ph.D.Mary Ellen Frustaci, M.A.S.Arun K. Kannan, Ph.D.Grazyna Rydzewska, M.D., Ph.D.Edward V. Loftus, M.D.Vipul Jairath, M.B., Ch.B., D.Phil.

    Find these authors on Roon

    EL
    Dr. Edward Loftus
    IBD · Mayo Clinic College of Medicine

    Summary

    In a phase 2 trial of once-daily oral icotrokinra for moderately to severely active ulcerative colitis, a clinical response at week 12 was more common with icotrokinra at each of three tested doses than with placebo.
    ELDr. Edward Loftus

    Dr. Edward Loftus

    Gastroenterology · Inflammatory Bowel Diseases
    Mayo Clinic
    edwardloftus